NEW YORK (360Dx) – French in vitro diagnostics firm Theradiag said on Monday that it has reached a deal with Immunodiagnostic Systems allowing access to that company's IDS-i10 automation system.
Under the terms of the deal, Theradiag is launching its Tracker biotherapy monitoring product line on the IDS-i10 system, it said, adding it has created a new commercial development program for Tracker tests to be based on the IDS technology. Tracker tests allow clinicians to monitor and optimize biotherapies treatments.
Theradiag will commercialize the Tracker biotherapy monitoring product line and associated reagents under its brand, beginning with the Lisa Tracker range of kits that are designed to monitor serum levels of circulating TNF-alpha, prescribed TNA-alpha inhibitors, and drug neutralizing antibodies to help physicians manage treatment regimens.
Additionally, UK-based Immunodiagnostic will distribute the Tracker technology under the Theradiag brand in 33 countries where the French firm has not had a presence, including in parts of Europe, such as Germany, as well as in Latin America as a whole, and in the Middle East.
Financial and other terms of the agreement were not disclosed.